Editas Medicine Inc (EDIT) USD0.0001

Sell:$1.91Buy:$1.92$0.10 (5.56%)

NASDAQ:1.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.91
Buy:$1.92
Change:$0.10 (5.56%)
Market closed | Prices delayed by at least 15 minutes
Sell:$1.91
Buy:$1.92
Change:$0.10 (5.56%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Key people

Gilmore O'Neill
President, Chief Executive Officer, Director
Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Linda C. Burkly
Executive Vice President, Chief Scientific Officer
Jessica Hopfield
Independent Chairman of the Board
Bernadette M. Connaughton
Independent Director
Andrew J. Hirsch
Independent Director
Elliott M. Levy
Independent Director
David T. Scadden
Independent Director
Click to see more

Key facts

  • EPIC
    EDIT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US28106W1036
  • Market cap
    $152.36m
  • Employees
    246
  • Shares in issue
    83.71m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.